Merck topped estimates and raised its profit forecast as cancer drug injection took off
Adjusted profit forecast moves to $2.77 to $2.82 a share from $2.66 to $2.76 as Keytruda Qlex sales reach $830 million
We haven't written up this one. Quartz has the full story — the link below goes straight to it.